Sparks commentary

Healthcare

Sparks

FDA approves Soleno Therapeutics’ (Nasdaq: SLN) Vykat XR
Published by Arron Aatkar, PhD

The US FDA has today approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release tablets. This marks the first FDA approved treatment to address hyperphagia in Prader-Willi syndrome, a rare neurodevelopmental condition (caused by a genetic abnormality) estimated to afflict one in every 15,000 babies in the US each year.

Latest

Industrials | Comment

THEON INTERNATIONAL (AMS: THEON) – additional order intake

Healthcare | Comment

Cereno Scientific (STO: CRNO-B) enters the FN25 Index

Industrials | Comment

AAC Clyde Space (OTCQX: AAC) share issue raising SEK64.5m

Industrials | Comment

Hercules (AIM: HERC) acquire Advantage NRG for up to £15.7m

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free